enGene Therapeutics Inc.ENGN
Price (close)
$1.92
Market cap
$128.7M
P/E
—
Revenue (TTM)
—
Net income
-$130.4M
Dividend yield
—
1-year total return
-70.5%
Net margin
—
Revenue growth
—
Debt / equity
0.11x
What enGene Therapeutics Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | — | -$24.5M | -$99.9M | -$55.1M | -$117.3M |
| Free cash flow | — | -$17.7M | -$25.1M | -$49.2M | -$100.7M |
More on ENGN.
- enGene Therapeutics Inc. summary
- enGene Therapeutics Inc. financial statements
- enGene Therapeutics Inc. key metrics
- enGene Therapeutics Inc. health scores and style box
- enGene Therapeutics Inc. earnings
- enGene Therapeutics Inc. dividends
- enGene Therapeutics Inc. valuation
- enGene Therapeutics Inc. ownership and insiders
- enGene Therapeutics Inc. peers
Figures from enGene Therapeutics Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.